Conexeu Sciences Completes Key Preclinical Study Phase for Regenerative Platform
Regenerative medicine company Conexeu Sciences has completed the 12-month P.R.O.O.F phase of its preclinical CXU program, a milestone it says supports a single-formulation strategy for medical aesthetics.
Reno, Nevada – Conexeu Sciences Inc. (NASDAQ: CNXU) announced the conclusion of its 12-month P.R.O.O.F preclinical study phase for its CXU regenerative platform. The company states this milestone signifies its commitment to the medical aesthetics sector, supported by a single formulation and its intellectual property strategy.
The reported study met its objectives across three pillars: a small-volume facial application, a large-volume application, and mechanical performance benchmarks for the material. These are preclinical findings that have not yet undergone peer review, and their clinical significance has not been established.
The CXU platform is designed around a single formula and platform, with an intellectual property strategy centered on this singular formulation rather than specific indications. It has been investigated for soft-tissue applications, including wound care and dental soft tissue, each requiring separate FDA authorization.
The next regulatory step involves a predicate-based 510(k) submission for the lead device candidate, targeted for the first quarter of 2027. This process will necessitate required testing, manufacturing, documentation, and review.
Conexeu operates within the medical aesthetics and regenerative tissue landscape, alongside larger entities such as AbbVie, Galderma, and Novo Nordisk. The company indicated that detailed findings from the preclinical study will be reserved for peer-reviewed publication.